688315-69-7Relevant academic research and scientific papers
Heterometallic compounds: Rare linear SMMs with divalent manganese ions
Li, Xiao-Lei,Min, Fan-Yong,Wang, Chao,Lin, Shuang-Yan,Liu, Zhiliang,Tang, Jinkui
, p. 3430 - 3438 (2015)
The reaction of Mn(OAc)2·4H2O and Ln(NO3)3·6H2O with N-(2-aminopropyl)-2-hydroxybenzamide and salicylic aldehyde in methanol/methylene dichloride produces yellow crystals of Ln2Mn(C7/
Hydrogen-bonding interactions, geometrical selectivity and spectroscopic properties of cobalt(III) complexes with unsymmetrical tridentate amine-amidato-phenolato type ligands
Mitsuhashi, Ryoji,Suzuki, Takayoshi,Sunatsuki, Yukinari,Kojima, Masaaki
, p. 131 - 137 (2013/06/27)
Four cobalt(III) complexes with the formula of [Co(Ln)2] - bearing tridentate amine-amidato-phenolato-type ligands (Ln: n = 1-4) were synthesized. All of the complexes were characterized by 1H NMR spectroscopy and X-ray an
Geometric selectivity, hydrogen-bonding interaction, and solvatochromism of Bis{N-(aminoalkyl)salicylamidato(2-)}cobaltate(III)
Mitsuhashi, Ryoji,Suzuki, Takayoshi,Sunatsuki, Yukinari,Kojima, Masaaki
supporting information; experimental part, p. 696 - 698 (2011/08/08)
Cobalt(III) complexes with N-(aminoalkyl)salicylamide dianions, Ln 2- (n = 14), have been prepared and their molecular and crystal structures have been determined. The geometric (mer- or fac-) selectivity of [Co(Ln)2]- com
Synthesis, molecular modeling and biological evaluation of PSB as targeted antibiotics
Cheng, Kui,Zheng, Qing-Zhong,Hou, Jin,Zhou, Yang,Liu, Chang-Hong,Zhao, Jing,Zhu, Hai-Liang
experimental part, p. 2447 - 2455 (2010/06/19)
We described here the design, synthesis, molecular modeling, and biological evaluation of a series of peptide and Schiff bases (PSB) small molecules, inhibitors of Escherichia coli β-Ketoacyl-acyl carrier protein synthase III (ecKAS III). The initial lead compound was reported by us previously, we continued to carry out structure-activity relationship studies and optimize the lead structure to potent inhibitors in this research. The results demonstrated that both N-(2-(3,5-dichloro-2-hydroxybenzylideneamino)propyl)-2-hydroxybenzamide (1f) and 2-hydroxy-N-(2-(2-hydroxy-5-iodobenzylideneamino)propyl)-4-methylbenzamide (3e) posses good ecKAS III inhibitory activity and well binding affinities by bonding Gly152/Gly209 of ecKAS III and fit into the mouth of the substrate tunnel, and can be as potential antibiotics agent, displaying minimal inhibitory concentration values in the range 0.20-3.13 μg/mL and 0.39-3.13 μg/mL against various bacteria.
